CT
CTMX.O
—
NASDAQ
Biotechnology
CytomX Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
539,5M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-29,3 %
ROE
-17,5 %
Net margin
-22,8 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,25
Open
$3,25
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
CytomX Therapeutics Inc is a biotechnology company that develops T-cell engaging bispecific therapies through strategic alliances with major pharmaceutical partners including Amgen, Bristol Myers Squibb, and Merck.
Business. CytomX Therapeutics Inc (CTMX.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target12,57
Analyst recommendations
8 analysts · consensus BuyBuy8
Hold0
Sell0
12-month price target
12,57
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-17,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CTMX.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
CytomX Therapeutics Inc (CTMX.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDCytomX Therapeutics maintains a capital structure characterized by zero debt, with a debt-to-equity ratio of 0.0. The balance sheet reports total assets of $151.6 million against total liabilities of $52.6 million, resulting in total equity of $99.0 million. Cash and equivalents stand at $12.7 million, which is modest relative to the company's burn rate. Operating cash flow is negative $75.6 million, indicating significant cash consumption during the period. The company trades at a price-to-book ratio of 6.24 and an enterprise value-to-revenue multiple of 7.94, reflecting market expectations for future clinical milestones rather than current earnings.
Profitability metrics are negative, consistent with the pre-commercial stage of the business. Return on equity is -17.54% and return on assets is -11.46%. The company reported a net income of -$17.4 million and an operating income of -$22.4 million. Revenue for the period was $76.2 million. Without cohort median data provided in the input, direct comparative analysis of profitability ratios against industry peers is omitted, but the negative returns are typical for clinical-stage biotechnology firms investing heavily in research and development.
Key takeaways
- CytomX operates with a debt-free balance sheet, holding $12.7 million in cash against $52.6 million in liabilities.
- The company generated $76.2 million in revenue, primarily driven by strategic alliances with major pharma partners like Amgen, BMS, and Merck.
- Operating cash flow is negative $75.6 million, indicating a cash burn rate that exceeds current cash reserves, necessitating future capital or milestone income.
- Profitability is negative with a ROE of -17.54% and ROA of -11.46%, typical for pre-commercial biotech firms.
- No immediate liquidity or dilution risks were flagged, though the cash runway appears limited without additional funding or revenue.
- Key clinical focus includes T-cell engaging bispecific therapies, with a notable collaboration with Merck for CX-801.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$3,17
Market cap
$617.8M
Enterprise valueⓘ
$605.1M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
6.2x
P / Tangible bookⓘ
6.2x
Tangible book
$99.0M
Net cashⓘ
$12.7M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-11.5%
ROEⓘ
-17.5%
Cash conversionⓘ
435.0%
CapEx / revenueⓘ
0.3%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships7 disclosed relationships · 1 type · extracted from filings & disclosures
Partners7
AMGEN INC.AMGN.OPartner95%Source ↗
Astellas Pharma Inc4503.TPartner95%Source ↗
Bristol-myers Squibb CoBMY.OPartner95%Source ↗
MERCK & CO., INC.MRK.OPartner95%Source ↗
MODERNA, INC.MRNA.OPartner95%Source ↗
REGENERON PHARMACEUTICALS, INC.REGN.OPartner95%Source ↗
Abbvie IncABBV.KPartner85%Source ↗
Supply chain
Vendors → CTMX ↔ Partners → Customers · click any node to drill
7 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,42
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-28 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,42 |
| Revenue | —no estimate | —no estimate | 36,5M USD |
| Operating income | —no estimate | —no estimate | -87,5M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy4
Buy4
Hold0
Sell0
Strong sell0
12-month price target$12,57 · Median $12,00
Low $6,00High $16,00
Operating income · consensus-87,5M USD
EPS surprise
+64,0 %
reported vs consensus · beat
Revenue surprise
+108,9 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$6,00
Mean$12,57
Median$12,00
High$16,00
Spot$3,17
+296.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-29,3 %Above median
Net Margin-22,8 %Above median
ROE-17,5 %Above median
Capex / Rev0,3 %Above median
D/E0,00Above median
Cash Conv4,35Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 4 294 100 sh23 grants13 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 118 000 @ $3,24grant · 2026-07-24
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 300 000 @ $6,09grant · 2026-02-02
- Chief Business Officer · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $6,09grant · 2026-02-02
- Chief Business Officer · Performance Stock Units (PSUs) → Common StockAcquired 50 000grant · 2026-02-02
- SVP, Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 250 000 @ $6,09grant · 2026-02-02
- Director, CEO · Stock Option (Right to Buy) → Common StockAcquired 980 000 @ $6,09grant · 2026-02-02
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 325 000 @ $6,09grant · 2026-02-02
- Chief Business Officer · Stock Option (Right to Buy) → Common StockAcquired 650 000 @ $3,74grant · 2025-10-20
- Director, CEO · Stock Option (Right to Buy) → Common StockAcquired 570 000 @ $2,90grant · 2025-09-26
- Chief Financial Officer · Performance Stock Units (PSUs) → Common StockAcquired 39 150grant · 2025-09-26
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 78 250 @ $2,90grant · 2025-09-26
- Chief Medical Officer · Performance Stock Units (PSUs) → Common StockAcquired 43 750grant · 2025-09-26
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 87 500 @ $2,90grant · 2025-09-26
- Director, CEO · Performance Stock Units (PSUs) → Common StockAcquired 285 000grant · 2025-09-26
- SVP, Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 36 300 @ $2,90grant · 2025-09-26
- SVP, Chief Scientific Officer · Performance Stock Units (PSUs) → Common StockAcquired 18 150grant · 2025-09-26
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- CytomX Therapeutics, Inc. Market data — financials · 2026-07-28
- reconciler_enqueue (reconciler) on CTMX.O · 2026-07-28
- CytomX Therapeutics Inc HA canonical relationships · 2026-07-28
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$150M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$27M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$10M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$36M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Sean A. McCarthyChairman of the Board, Chief Executive Officer
Insider activity
Net selling0 buys · 6 sellsnet -$1,7M5 insiders · last 365d
- Chief Financial Officer · Common StockSold 1 624 @ $3,05$5K · 2026-06-15
- Chief Medical Officer · Common StockSold 21 279 @ $6,42$137K · 2026-03-17
- Director, CEO · Common StockSold 118 969 @ $6,42$764K · 2026-03-17
- SVP, Chief Scientific Officer · Common StockSold 31 492 @ $6,42$202K · 2026-03-17
- Chief Financial Officer · Common StockSold 19 323 @ $6,42$124K · 2026-03-17
- Chief Business Officer · Common StockOther 20 000 · 2026-02-02
- Chief Medical Officer · Common StockOther 75 000 · 2026-02-02
- SVP, Chief Scientific Officer · Common StockOther 60 000 · 2026-02-02
- Chief Financial Officer · Common StockOther 90 000 · 2026-02-02
- Director, CEO · Common StockOther 210 000 · 2026-02-02
- Director, CEO · Class A Common StockSold 101 793 @ $4,54$462K · 2025-11-06
Short positioning
40.3Mshares short+13.4% vs prior
10.38days to cover
68.3%short of daily vol
3.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CTMX.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Shares outstanding (annual): 170.19MUnknown
- Total liabilities (annual): USD 52.56MUnknown
- Revenue (annual): USD 76.2MUnknown
- R&D expense (annual): USD 68.73MUnknown
- Pre-tax income (annual): USD -17.13MUnknown
- Current liabilities (annual): USD 46.62MUnknown
- Capex (annual): USD 220KUnknown
- Total assets (annual): USD 151.57MUnknown
- Net income (annual): USD -17.37MUnknown
- Operating income (annual): USD -22.36MUnknown
- Shareholders' equity (annual): USD 99.01MUnknown
- Total operating expenses (annual): USD 98.56MUnknown
- Current assets (annual): USD 143.92MUnknown
- Operating cash flow (annual): USD -75.59MUnknown
- Cash & equivalents (annual): USD 12.67MUnknown
- Total liabilities (annual): USD 120.99MUnknown
- Current liabilities (annual): USD 85.77MUnknown
- Revenue (annual): USD 138.1MUnknown
- Pre-tax income (annual): USD 32.09MUnknown
- Current assets (annual): USD 107.31MUnknown
- Capex (annual): USD 310KUnknown
- R&D expense (annual): USD 83.38MUnknown
- Operating cash flow (annual): USD -86.23MUnknown
- Net income (annual): USD 31.87MUnknown
Showing 24 of 30 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-28 04:34 UTCFILINGMaterial 8-K
2026-07-24INSIDERFuchs Charles S. acquired 118.0k sh Stock Option (Right to Buy) — Director
2026-06-17 00:00 UTCINSIDER8 insider transactions — 2026-06 7 derivative
2026-06-17 00:00 UTCINSIDER8 insider transactions — 2026-06 7 derivative
2026-06-17INSIDERJones Elaine V acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERSu Zhen acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERYoung Matthew P. acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERMeyers James R acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERMohindru Mani acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERGilbert Halley E acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERAshworth Alan acquired 59.0k sh Stock Option (Right to Buy) — Director
2026-06-15INSIDEROgden Christopher sold 1.6k sh — Chief Financial Officer ~$5k
2026-03-17 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $1.2M
2026-03-17 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $1.2M
2026-03-17INSIDERChu Yu-Waye sold 21.3k sh — Chief Medical Officer ~$137k
2026-03-17INSIDERMcCarthy Sean A. sold 119.0k sh — Director, CEO ~$764k
2026-03-17INSIDERBELVIN MARCIA sold 31.5k sh — SVP, Chief Scientific Officer ~$202k
2026-03-17INSIDEROgden Christopher sold 19.3k sh — Chief Financial Officer ~$124k
2026-02-02 00:00 UTCINSIDER11 insider transactions — 2026-02 6 derivative
2026-02-02 00:00 UTCINSIDER11 insider transactions — 2026-02 6 derivative
2026-02-02INSIDERLester Rachael transacted 20.0k sh — Chief Business Officer
2026-02-02INSIDERChu Yu-Waye transacted 75.0k sh — Chief Medical Officer
2026-02-02INSIDERBELVIN MARCIA transacted 60.0k sh — SVP, Chief Scientific Officer
2026-02-02INSIDEROgden Christopher transacted 90.0k sh — Chief Financial Officer
2026-02-02INSIDERMcCarthy Sean A. transacted 210.0k sh — Director, CEO
2026-02-02INSIDERLester Rachael acquired 50.0k sh Stock Option (Right to Buy) — Chief Business Officer
2026-02-02INSIDERChu Yu-Waye acquired 300.0k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-02-02INSIDERBELVIN MARCIA acquired 250.0k sh Stock Option (Right to Buy) — SVP, Chief Scientific Officer
2026-02-02INSIDERMcCarthy Sean A. acquired 980.0k sh Stock Option (Right to Buy) — Director, CEO
2026-02-02INSIDEROgden Christopher acquired 325.0k sh Stock Option (Right to Buy) — Chief Financial Officer
Showing the 40 most recent of 55 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage